Motpoly XR, a Once-Daily Formulation of Lacosamide, Now Available

Motpoly XR™ (lacosamide) extended-release capsules are now available for the treatment of partial-onset seizures in adult and pediatric patients weighing at least 50kg. 

Motpoly XR is bioequivalent to Vimpat^® (lacosamide) film-coated tablets and provides a new once-daily option at equivalent doses. The approval was based on the relative bioavailability of Motpoly XR compared with immediate-release lacosamide in healthy adults. 

For adults 17 years of age and older, the recommended initial dosage of Motpoly XR is 200mg once daily as monotherapy and 100mg once daily as adjunctive therapy. For pediatric patients weighing at least 50kg, the recommended initial dosage of Motpoly XR is 100mg once daily. Dosage should be increased based on clinical response and tolerability, no more frequently than once per week.

Dosage adjustment is recommended for patients with severe renal impairment and for those with mild or moderate hepatic impairment. Motpoly XR is not recommended for patients with severe hepatic impairment.

Motpoly XR is a Schedule V controlled substance. It is supplied as 100mg-, 150mg-, and 200mg strength capsules in 60-count bottles. 

Aucta Pharmaceuticals is offering a copay savings card for Motpoly XR to eligible patients.